Together Against Bacterial Infections

07.06.2004

Vienna - Intercell AG has signed a license agreement with the pharmaceutical company Merck & Co., Inc. for the development of certain bacterial vaccines and an option to develop antibody products. As a result of this extended agreement, Intercell will receive upfront-, license-, and milestone-payments for a vaccine product. If Merck exercises the option for an antibody product, the Vienna-based company will obtain additional payments and royalty payments on product sales. Merck receives exclusive worldwide rights to commercialize any products that may be developed under the agreement. Further financial details were not disclosed. This license agreement is the continuation of a research collaboration with Merck that began three years ago. During this collaboration, Intercell applied its Antigen Identification Program (AIP) to identify relevant antigens directed towards a specific bacterial target.

Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these...

The Paracelsus Private Medical University (PMU) in Salzburg is to build a new research center for spinal cord injuries. The €70m construction tab will be picked up by Dietrich Mateschitz, the owner of Red Bull. Other partners in...

Vienna – In Affiris they trust – as a proof of their faith, two big investors poured €25 million into the Austrian developer of a possible Alzheimer drug. Venture fonds Santo VC, the investment vehicle of the German billionaires...

Innsbruck – An Austrian physician has been fined EUR4,500 in a case involving a controversial stem cell therapy for incontinence. In early August, an Innsbruck Regional Court adjudged Hannes Strasser, who developed the method, at...

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

Vienna – Austrian Intercell AG has lost its partner Merck & Co after termination of a Phase II/III trial with Intercell’s vaccine candidate V710 against Staphylococcus aureus, the most frequent cause of hospital-acquired...

Vienna - f-star, an antibody specialist, today announced the closing of aEUR 15 Million financing. The investment was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star’s existing investors, Atlas...

Partner-Events

Stockholm (SE)

Wien (A)

Product of the week

BioShake Series

The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more